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An analysis of direct medical care cost differences be-
tween Alzheimer’s and non-Alzheimer’s patients enrolled
in a managed care organization (MCO) was conducted.
OBJECTIVE: The purpose of this study was to determine
a difference between direct medical costs of Alzheimer’s
patients and elderly non-Alzheimer’s patients.
METHODS: Direct medical costs were collected for a
1-year period for the MCOs Alzheimer’s population con-
sisting of 266 patients. Direct medical costs were also
collected for this period for the population of elderly
patients without a diagnosis of Alzheimer’s disease (AD)
(n  13,553). These costs did not include nursing home
or prescription costs. Medical costs from the population
databases were compared.
RESULTS: A greater proportion of AD patients were
hospitalized during the year (38.0% versus 16.3%) and
mean length of hospital stay was slightly longer for AD
patients (5.7 days versus 5.4 days). On a per patient ba-
sis, AD patients received more inpatient hospital services
(51.5 versus 43.3), outpatient hospital services (11.6 ver-
sus 10.6), and physician office services (15.8 versus 14.8)
than non-AD patients. As a proportion of total costs,
non-AD patients had a greater proportion associated
with outpatient services (67.9% versus 43.8%), whereas
AD patients had a higher proportion associated with in-
patient services (48.9% versus 30.2%). The mean cost
per person for services for AD patients was $4440.67
(sd  7148.14) compared to $2753.12 (sd  5465.61)
for non-AD patients, yielding a difference of $1687.55
per patient that may be attributed to AD.
CONCLUSION: The Alzheimer’s population of this
MCO utilized more services and had a higher mean an-
nual cost per person than the non-Alzheimer’s elderly
population.
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OBJECTIVES: To construct a disease-based simulation
model to estimate the clinical and economic outcomes of
treating bipolar disorder with mood stabilizers.
METHODS: Information obtained from the literature
and interviews with clinical psychiatrists were utilized to
develop a conceptual model of bipolar disorder and its
treatment. In a conceptual framework utilizing properties
of the Markov process, seven health states were identi-
fied. A treatment algorithm that captures modal prescrib-
ing patterns was developed to model the use of four
mood stabilizers, alone or in combination, and three cat-
egories of adjunctive agents, with mood stabilizer ther-
apy changing in response to transitions in health states.
Healthcare resources in the model include emergency de-
partment visits, hospitalization, office visits, laboratory
tests, procedures and drug therapy, with resource con-
sumption varying with mood stabilizer treatment and
health state.
RESULTS: A Monte Carlo computer simulation model
of bipolar disorder was developed. The simulation dura-
tion, cohort size and initial health state can be varied. All
base-case estimates can be modified to reflect a diversity
of clinical and economic data and practice patterns. Al-
ternative treatments and treatment algorithms can be in-
corporated. The simulation allows cycle length duration
to be varied for specific health states. Reports present
clinical and economic results for each simulation run.
CONCLUSIONS: Utilizing a discrete-state Monte Carlo
simulation, data from numerous sources can be combined
to estimate the clinical outcomes and economic conse-
quences of using one or more mood stabilizers in various
health states experienced by patients with bipolar disorder.
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OBJECTIVE: This study examined the medical utiliza-
tion and cost experiences of ambulatory Medicaid pa-
tients diagnosed with schizophrenia.
METHODS: A historical cohort design was used. Eligi-
ble patients between 18 and 65 years were assigned to
risperidone (N  1438), clozapine (N  845), haloperi-
dol (N  1029), or other conventional antipsychotic
(N  1503) drug cohorts based on type of antipsychotic
drug that was first used during a 1-year window of time.
Using an intent-to-treat approach, we report total and
schizophrenia-related hospital, emergent care, drug, out-
patient visit, laboratory use, and cost experience based
on paid claims data 6 months before and 12 months after
the index date. Multiple regression analyses were used to
determine the strength of the association of drug use with
costs of care, controlling for demographic characteristics
and baseline use of medical care services.
RESULTS: Medical care service use declined 20% or
more during the 12-month follow-up period. Schizophre-
nia-related costs comprised slightly over 70% of total
costs for patients in the clozapine cohort, and slightly
over 40% of total costs for the other cohorts. OLS re-
gression explained approximately 50% of the variance in
patient costs of care. Higher total and schizophrenia-
related costs were associated with cost of care during
baseline, clozapine use, risperidone use, number of
months of antipsychotic drug use, and comorbidities.
